My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02
Diseases and Conditions Researched
Bladder; Brain and Nervous System; Breast - Female; Colon; Esophagus; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Endocrine System; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid
What is the purpose of this trial?
This is a multicenter, non-randomized, open-label study designed to evaluate fou r treatment regimens in patients with advanced cancer for whom there is no avail able, beneficial treatment. Patients with HER2 overexpression, amplification, or activating mutation will be treated with Herceptin/Perjeta; those with epiderm al growth factor receptor (EGFR), with Tarceva; those with BRAF-activating mutat ion, with Zelboraf; and those with Hedehog pathway potentially clinically releva nt mutation, with Erivedge. Treatment will continue until disease progression or unacceptable toxicity occurs. Study is expected to last up to 5 years.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.